Renibus Therapeutics Inc Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Renibus Therapeutics is a clinical-stage, small to mid-sized biotechnology company based in Southlake, Texas, focused on preventing disease progression and protecting organ function in cardiorenal diseases. Its approach centers on activating cytoprotective pathways and organ preconditioning to improve patient outcomes. The lead program, RBT-1, is in Phase 2 for reducing postoperative complications after cardiothoracic surgery and is slated to move into Phase 3 for that indication. The broader RBT portfolio includes RBT-2 and RBT-3, developed to address CKD progression and nephrotoxicity risk, with development activities anticipated in the near term. Recent activity includes presenting data from the Phase 3 PROTECT trial of RBT-1 at the 106th American Association for Thoracic Surgery Annual Meeting in 2026.

Sign up for free to view info

Company overview Employee directory